Journal article
Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy
American journal of nuclear medicine and molecular imaging, v 8(6), pp 407-414
20 Dec 2018
PMID: 30697460
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The role of fluorodeoxyglucose-positron emission tomography (FDG-PET) has been well established in assessment of lymphoma, including non-Hodgkin lymphoma (NHL). The aim of this study was to compare changes and survival predictive values of various quantification parameters of FDG-PET/CT in patients with relapsing/refractory lymphoma before and after radioimmunotherapy (RIT). Data from 17 patients with relapsing/refractory NHL, treated with targeted RIT after chemotherapy/radiotherapy, were retrospectively collected. FDG-PET/CT scans were performed approximately three months before and six months after RIT. An adaptive contrast-oriented thresholding algorithm was used to segment lesions on the FDG-PET images. Wilcoxon signed-rank tests were used to assess changes in SUVmax, SUVmean, partial volume-corrected SUVmean (pvcSUVmean), total lesion glycolysis (TLG), and pvcTLG before and after treatment. The patients were followed up after completing RIT for up to 10 years. Kaplan-Meier and Cox regression analyses evaluated the association between the quantification parameters and survival data. In the survived group, the decrease in mean percentage of change for TLG and pvcTLG was greater than SUVmax, SUVmean and pvcSUVmean [TLG: 253.9 to 106.9, -81.4%;
P
= 0.052 and pvcTLG: 368.9 to 153.3, -58.4%;
P
= 0.04]. In addition, overall survival (OS) was shorter in patients with pre-RIT pvcTLG more than 644 compared to those below this value (log-rank
P
< 0.01). In univariate Cox regression for OS, a higher baseline pvcTLG was a significant prognostic factor (HR: 6.8,
P
= 0.02). Our results showed that pre-treatment pvcTLG was the best predictor of OS in patients with relapsing/refractory NHL following RIT.
Metrics
1 Record Views
Details
- Title
- Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy
- Creators
- Raheleh Taghvaei - Hospital of the University of PennsylvaniaMahdi Zirakchian Zadeh - Hospital of the University of PennsylvaniaReza Sirous - University of Maryland Medical CenterSara Pourhassan Shamchi - Hospital of the University of PennsylvaniaWilliam Y Raynor - Drexel UniversitySiavash Mehdizadeh Seraj - Hospital of the University of PennsylvaniaMateen Moghbel - Stanford MedicineShiyu Wang - Hospital of the University of PennsylvaniaThomas J Werner - Hospital of the University of PennsylvaniaHongming Zhuang - Children's Hospital of PhiladelphiaAbass Alavi - Hospital of the University of Pennsylvania
- Publication Details
- American journal of nuclear medicine and molecular imaging, v 8(6), pp 407-414
- Publisher
- e-Century Publishing Corporation
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiology (Radiologic Sciences)
- Web of Science ID
- WOS:000455453400005
- Other Identifier
- 991019350675404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Radiology, Nuclear Medicine & Medical Imaging